# Autonomix Medical, Inc.: financial statements, quarterly

AMIX · Nasdaq · CIK 1617867 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/amix.md) · [Financials](/companies/amix/financials.md) · [Filings](/companies/amix/filings.md) · [Insiders](/companies/amix/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amix/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001437749-24-034230.md) | [0.0](/filings/0001437749-25-003669.md) | [0.0 d](/filings/0001437749-25-018831.md) | [0.0](/filings/0001437749-25-026564.md) | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-26-027429.md) | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-26-027429.md) |
| Research and development | $m | [0.5](/filings/0001437749-24-034230.md) | [0.7](/filings/0001437749-25-003669.md) | [0.7 d](/filings/0001437749-25-018831.md) | [1.0](/filings/0001437749-25-026564.md) | [1.2](/filings/0001437749-25-034517.md) | [1.0](/filings/0001437749-26-003816.md) | [1.6 d](/filings/0001437749-26-018573.md) | [1.6](/filings/0001437749-26-027429.md) | [2.4](/filings/0001437749-25-034517.md) | [1.7](/filings/0001437749-26-003816.md) | [1.5 d](/filings/0001437749-26-018573.md) | [1.5](/filings/0001437749-26-027429.md) |
| Operating income | $m | [(5.8)](/filings/0001437749-24-034230.md) | [(2.9)](/filings/0001437749-25-003669.md) | [(2.4) d](/filings/0001437749-25-018831.md) | [(2.8)](/filings/0001437749-25-026564.md) | [(2.8)](/filings/0001437749-25-034517.md) | [(2.7)](/filings/0001437749-26-003816.md) | [(3.3) d](/filings/0001437749-26-018573.md) | [(3.4)](/filings/0001437749-26-027429.md) | [(7.5)](/filings/0001437749-25-034517.md) | [(3.3)](/filings/0001437749-26-003816.md) | [(2.7) d](/filings/0001437749-26-018573.md) | [(2.8)](/filings/0001437749-26-027429.md) |
| Interest expense | $m | [0.0](/filings/0001437749-24-034230.md) | [0.0](/filings/0001683168-24-000918.md) | [0.0 d](/filings/0001437749-25-018831.md) | [0.0](/filings/0001437749-25-026564.md) | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-25-026564.md) | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | not reported |
| Income tax | $m | [0.0](/filings/0001437749-24-034230.md) | [0.0](/filings/0001437749-25-003669.md) | [0.0 d](/filings/0001437749-25-018831.md) | [0.0](/filings/0001437749-25-026564.md) | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-26-027429.md) | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-26-027429.md) |
| Net income | $m | [(6.0)](/filings/0001437749-25-003669.md) | [(3.1)](/filings/0001437749-25-003669.md) | [(15.4)](/filings/0001437749-25-018831.md) | [(2.7)](/filings/0001437749-26-003816.md) | [(2.8)](/filings/0001437749-26-003816.md) | [(2.7)](/filings/0001437749-26-003816.md) | [(11.4)](/filings/0001437749-25-018831.md) | [(3.3)](/filings/0001437749-26-027429.md) | [(7.5)](/filings/0001437749-26-003816.md) | [(3.3)](/filings/0001437749-26-003816.md) | [(2.7) d](/filings/0001437749-26-018573.md) | [(2.7)](/filings/0001437749-26-027429.md) |
| Diluted EPS | $ per share | not reported | [(0.23)](/filings/0001683168-24-000918.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(8.78)](/filings/0001437749-24-034230.md) | [(3.07)](/filings/0001437749-25-003669.md) | not reported | [(2.20)](/filings/0001437749-25-026564.md) | [(2.27)](/filings/0001437749-25-034517.md) | [(1.46)](/filings/0001437749-26-003816.md) | not reported | [(22.69)](/filings/0001437749-26-027429.md) | [(1.38)](/filings/0001437749-25-034517.md) | [(0.36)](/filings/0001437749-26-003816.md) | not reported | [(5.02)](/filings/0001437749-26-027429.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [1.2](/filings/0001683168-24-000918.md) | [8.6](/filings/0001437749-25-018831.md) | [6.8](/filings/0001437749-24-026451.md) | [5.2](/filings/0001437749-24-034230.md) | [11.8](/filings/0001437749-25-003669.md) | [9.1](/filings/0001437749-26-018573.md) | [8.6](/filings/0001437749-25-026564.md) | [7.5](/filings/0001437749-25-034517.md) | [9.9](/filings/0001437749-26-003816.md) | [7.0](/filings/0001437749-26-027429.md) | [3.5](/filings/0001437749-26-027429.md) |
| Current assets | $m | not reported | [1.7](/filings/0001683168-24-000918.md) | [9.4](/filings/0001437749-25-018831.md) | [7.1](/filings/0001437749-24-026451.md) | [5.4](/filings/0001437749-24-034230.md) | [11.9](/filings/0001437749-25-003669.md) | [9.6](/filings/0001437749-26-018573.md) | [9.0](/filings/0001437749-25-026564.md) | [7.9](/filings/0001437749-25-034517.md) | [10.2](/filings/0001437749-26-003816.md) | [7.6](/filings/0001437749-26-027429.md) | [4.0](/filings/0001437749-26-027429.md) |
| Total assets | $m | not reported | [1.8](/filings/0001683168-24-000918.md) | [9.4](/filings/0001437749-25-018831.md) | [7.1](/filings/0001437749-24-026451.md) | [5.4](/filings/0001437749-24-034230.md) | [12.0](/filings/0001437749-25-003669.md) | [9.8](/filings/0001437749-26-018573.md) | [9.0](/filings/0001437749-25-026564.md) | [7.9](/filings/0001437749-25-034517.md) | [10.2](/filings/0001437749-26-003816.md) | [7.6](/filings/0001437749-26-027429.md) | [4.0](/filings/0001437749-26-027429.md) |
| Current liabilities | $m | not reported | [1.0](/filings/0001683168-24-000918.md) | [0.8](/filings/0001437749-25-018831.md) | [0.8](/filings/0001437749-24-026451.md) | [1.3](/filings/0001437749-24-034230.md) | [2.2](/filings/0001437749-25-003669.md) | [1.7](/filings/0001437749-26-018573.md) | [2.0](/filings/0001437749-25-026564.md) | [1.5](/filings/0001437749-25-034517.md) | [1.7](/filings/0001437749-26-003816.md) | [1.7](/filings/0001437749-26-027429.md) | [0.8](/filings/0001437749-26-027429.md) |
| Total liabilities | $m | not reported | [7.4](/filings/0001683168-24-000918.md) | [1.8](/filings/0001437749-25-018831.md) | [1.8](/filings/0001437749-24-026451.md) | [2.3](/filings/0001437749-24-034230.md) | [2.2](/filings/0001437749-25-003669.md) | [1.7](/filings/0001437749-26-018573.md) | [2.0](/filings/0001437749-25-026564.md) | [1.5](/filings/0001437749-25-034517.md) | [1.7](/filings/0001437749-26-003816.md) | [1.7](/filings/0001437749-26-027429.md) | [0.8](/filings/0001437749-26-027429.md) |
| Long-term debt | $m | not reported | [1.5](/filings/0001683168-24-000918.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | [0.0](/filings/0001437749-25-003669.md) | not reported | not reported | [1.1](/filings/0001437749-25-003669.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(2.9)](/filings/0001437749-25-003669.md) | [(5.6)](/filings/0001437749-25-003669.md) | [7.6](/filings/0001437749-26-018573.md) | [5.3](/filings/0001437749-26-003816.md) | [3.0](/filings/0001437749-26-003816.md) | [9.7](/filings/0001437749-26-003816.md) | [8.1](/filings/0001437749-26-027429.md) | [7.0](/filings/0001437749-26-027429.md) | [6.4](/filings/0001437749-26-003816.md) | [8.6](/filings/0001437749-26-003816.md) | [5.9](/filings/0001437749-26-027429.md) | [3.2](/filings/0001437749-26-027429.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,144) d](/filings/0001437749-24-034230.md) | [(2,556) d](/filings/0001437749-25-003669.md) | [(6,648)](/filings/0001437749-25-018831.md) | [(1,852)](/filings/0001437749-25-026564.md) | [(1,596) d](/filings/0001437749-25-034517.md) | [(2,301) d](/filings/0001437749-26-003816.md) | [(8,258)](/filings/0001437749-25-018831.md) | [(2,604)](/filings/0001437749-26-027429.md) | [(3,817) d](/filings/0001437749-25-034517.md) | [(2,969) d](/filings/0001437749-26-003816.md) | [(2,892) d](/filings/0001437749-26-018573.md) | [(3,544)](/filings/0001437749-26-027429.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001437749-24-034230.md) | [16.0 d](/filings/0001437749-25-003669.md) | [19.0](/filings/0001437749-25-018831.md) | [5.0](/filings/0001437749-25-026564.md) | [0.0 d](/filings/0001437749-25-034517.md) | [5.0 d](/filings/0001437749-26-003816.md) | [14.0](/filings/0001437749-25-018831.md) | [0.0](/filings/0001437749-25-026564.md) | [0.0 d](/filings/0001437749-25-034517.md) | [7.0 d](/filings/0001437749-26-003816.md) | [3.0 d](/filings/0001437749-26-018573.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-12-31) | Q3 FY2024 (2023-12-31) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.0](/filings/0001683168-24-000918.md) | [13.8](/filings/0001683168-24-000918.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 971,043 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001437749-26-027429.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.